Article | September 9, 2024

Clinical Trial Diversity From A Disclosure Perspective

Source: Citeline
pediatrics patient diversity iStock-1249263068

Diversity in clinical trials has become a critical focus, especially with the FDA’s updated diversity plan guidance. Fenwick Eckhardt of Citeline Consulting outlined five key criteria that sponsors must report on, including disease overview, product development plans, enrollment goals, and retention strategies for underrepresented groups. However, challenges persist, such as the lack of harmonization between FDA guidelines and global or federal reporting standards on race and ethnicity. Additionally, age and other demographics like LGBTQIA+ populations and people with disabilities require more nuanced approaches.

Eckhardt and Sylvia Baedorf Kassis from the Multi-Regional Clinical Trials Center emphasized the importance of incorporating real-world data and social determinants of health into trial designs to address access and equity issues. Clear, plain-language communication is also crucial for building trust with underrepresented populations. As the FDA's mandate takes full effect in 2025, sponsors are encouraged to take proactive steps now to meet and exceed diversity expectations in clinical trials.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader